Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
The Pharma Data
JANUARY 31, 2021
We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. . TOKYO and CAMBRIDGE, England , Feb. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. SOURCE Sosei Heptares.
Let's personalize your content